XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Christmas

<< Previous

Bullboard Posts

Next >>

Comment by SSeahawk053on Dec 22, 2021 1:21am

96 Views

Post# 34253292

RE:RE:RE:Christmas

Ha Ha...well then there is no way that this DINGBAT would go up against an OXFORD Graduate dude like you SpaceLab. I do appreciate your honesty though. My other OXFORD Graduate friends tend to call themselves Alumni or baccalaureate, licentiate, and sometimes valedictorians but you would know that already. You prefer to call yourself an OXFORD dude, how Calgary of you to do so. Thank you.

Wishing you a very healthy and Prosperou$$ New Year dude.

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment